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Abstract
Rationale Several studies have suggested that modulation of
the glutamatergic system via metabotropic glutamate recep-
tors (mGlu) could be a new way to achieve antipsychotic-like
activity. LSP1-2111, the group III mGlu receptor orthosteric
agonist, with a high affinity towards mGlu4 receptors, was
previously shown to exhibit antipsychotic-like action in ani-
mal models displaying positive symptoms of schizophrenia.
Objectives Here, we decided to investigate the possible role
of LSP1-2111 in models of negative (social interaction) and
cognitive (NOR) symptoms of psychosis. We also investi-
gated the involvement of 5-HT1A receptors in the LSP1-
2111-induced antipsychotic effects. Apart from the above-
mentioned models of negative and cognitive symptoms,
MK-801 and amphetamine-induced hyperactivity tests, plus
the DOI-induced head twitches in mice as models for pos-
itive symptoms of psychosis, were used in this part of the
investigations.
Results LSP1-2111 (0.5, 2, and 5 mg/ kg) dose-dependently
inhibited MK-801-induced deficits in social interaction and
NOR tests. The effects of the drug were antagonized by
5-HT1A antagonist, WAY100635 (0.1 mg/kg). A similar
inhibition of LSP1-2111-induced effects was observed in
models of positive symptoms of schizophrenia. Moreover,
the concomitant administration of subeffective doses of
LSP1-2111 (0.3-0.5 mg/kg) with a subeffective dose of 5-
HT1A agonist, (R)-(+)-8-Hydroxy-DPAT (0.01 mg/kg), in-
duced a clear antipsychotic-like effect in all of the procedures
used.
Conclusions Altogether, we propose that the activation of
group III mGlu receptors may be a promising target for the
development of novel antipsychotic drugs, towards not only
positive but also negative and cognitive symptoms. The
action of the compound is 5-HT1A-dependent.
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Introduction
Psychotic disorders constitute the group of mental diseases
affecting nearly 5 million of the population in Europe, which
places them in the sixth place among the most frequently
diagnosed psychiatric disorders (Andlin-Sobocki and Rössler
2005). However, it is regarded as the most serious psychiatric
illness that, in most cases, affects young people between 18
and 35 years of age, in their most effective period of life,
excluding them from a normal existence, such as being able to
start a family and continue with employment (Cramer et al.
1992; Mueser and McGurk 2004).
Metabotropic glutamate receptor (mGlu) ligands have
been recently considered as an alternative to the presently
used neuroleptic therapy, possibly improving antipsychotic
treatment. The family of mGlu receptors is divided into
three classes according to the sequence homology, pharma-
cology, and the second messenger system they activate.
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Group I involves mGlu1 and mGlu5 subtypes, group II
consists of mGlu2 and mGlu3 receptors, and mGlu4, mGlu6,
mGlu7, and mGlu8 constitute the third group of mGlu
receptors (Pin and Duvoisin 1995).
Key evidence for the involvement of mGlu receptors in
psychosis originated in the clinical report by Patil et al.
(2007), showing that the treatment with LY2140023 (an
mGlu2/3 agonist) was safe and well-tolerated, plus effective
in reducing both positive and negative symptoms when
compared to the placebo (Patil et al. 2007).
However, the results of the subsequent studies appeared
to be inconclusive because LY2140023 monohydrate and
the active control olanzapine did not separate from the
placebo in the treatment of patients with acutely exacerbated
schizophrenia (Kinon et al. 2011). That is why the project
was stopped (August 29, 2012; Lilly press release). How-
ever, the very recent report from Addex (November 5, 2012;
Addex press release) demonstrated a successful phase 2a
clinical study with ADX71149, the mGlu2 receptor PAM.
These studies do not shatter the credibility of group II mGlu
ligands as the new target in antipsychotic therapy due to the
effect of the placebo observed in schizophrenia clinical trials
representing a growing problem that interferes with the
signal detection for treatments (Alphs et al. 2012). The
important matter is that mGlu receptor ligands seem to
possess the unique characteristic of not targeting dopamine
receptors (Cartmell et al. 2000a, b; Weinberger 2007).
Recently, the third and the largest group of mGlu recep-
tors has started to be broadly investigated in the field of
neuropsychopharmacology. The first brain-penetrating agent
selective towards this group, ACPT-I, was characterized in
1997 (Acher et al. 1997). The papers published showed the
efficacy of the compound in several behavioral models of the
positive symptoms of schizophrenia, such as MK-801 and
amphetamine-induced hyperlocomotion, as well as in DOI-
induced head twitches in mice (Pałucha-Poniewiera et al.
2008). Later on, a successor of ACPT-I, which displayed a
higher potency at mGlu4 over mGlu7/mGlu8 receptors by 30-
fold, LSP1-2111, was shown to be active in the same models
(Wierońska et al. 2012b). The results indicate that group
III mGlu receptors, which share the same presynaptic ex-
pression as group II mGlu receptors, meaning that the stim-
ulation of both groups inhibits the release of glutamate
(Cartmell and Schoepp 2000), may be considered as a new
target for future antipsychotics. However, there is no data
about the efficacy of the compounds in the models of nega-
tive and cognitive symptoms of psychosis. The mechanism
of action of the drugs has also been poorly investigated so
far. Therefore, in the present study we focused on the effica-
cy of LSP1-2111 in models of negative and cognitive dis-
turbances. In addition, the involvement of the serotonergic
system in antipsychotic activity, with a special consideration
for the 5-HT1A receptors, was reported several times (see
Ohno 2011 for review). Not only the antipsychotic effect of
5-HT1A agonist, 8-OH-DPAT, was reported (Bubeníková-
Valesová et al. 2007), but also activity towards that subtype
of the serotonergic receptor was established for some atypical
antipsychotics (Meltzer et al. 2003). Therefore, in the present
study we used WAY100635, a 5-HT1A antagonist (Fletcher et
al. 1996), and (R)-(+)-8-Hydroxy-DPAT hydrobromide, a 5-
HT1A agonist (Wood et al. 2000), which were co-administered
with effective and subeffective doses of LSP1-2111, respec-
tively, in order to determine the role of the serotonergic
receptor in LSP1-2111-mediated action.
The social interaction test was performed as predictive for
negative symptoms of the disease and novel object recogni-
tion (NOR) as predictive for cognitive disturbances. The
standard models of positive symptoms of schizophrenia, such
as the MK-801 or amphetamine-induced hyperactivity test
and DOI-induced head twitches were also used in our experi-
ments. In the interaction studies, the action of the effective
dose of LSP1-2111 (5 mg/kg) was blocked by WAY100635
(0.1 mg/kg) administration while the subeffective doses of
LSP1-2111 (0.3–0.5 mg/kg, depending on the experimental
design) were enhanced by the subeffective dose of (R)-(+)-8-
Hydroxy-DPAT hydrobromide (0.01 mg/kg). Our result
shows that the proposed antipsychotic action of LSP1-2111
involves the 5-HT1A receptors.
Materials and methods
Animals and housing Male Albino Swiss mice (20–25 g)
were used both for the hyperactivity tests and DOI-induced
head twitches. Male Wistar rats (200–220 g) were used in the
social interaction and novel object recognition tests. The
animals were kept under a 12:12 light–dark cycle at a room
temperature of 19–21 °C with free access to food and water.
Each experimental group consisted of eight to ten animal-
s/dose, and the animals were used only once in each test. All
of the animals were experimentally naive prior to testing. For
all the experiments in mice, the compounds were injected at a
volume of 10 mL/kg and in rats at a volume of 1 mL/kg. The
experiments were performed by an observer blind to the
treatment and were conducted according to the procedures
approved by the Animal Care and Use Committee at the
Institute of Pharmacology, Polish Academy of Sciences in
Krakow.
Drugs LSP1-2111 Acher WO2007 052169 was synthesized
in Dr. Francine Acher’s laboratory and was dissolved in
water, and then the pH was adjusted with NaOH to 7.0 before
the stock solution was dissolved in a saline (Acher et al. 2007).
MK-801, WAY100635, (R)-(+)-8-Hydroxy-DPAT hydrobro-
mide (Tocris), DOI and D-amphetamine sulfate (Sigma-
Aldrich, St. Louis, USA) were dissolved in 0.9 % NaCl.
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The psychostimulants (MK-801, amphetamine, and DOI)
were administered at the same doses and schedule as in our
previous studies (Pałucha-Poniewiera et al. 2008; Wierońska
et al. 2011, 2012a, b). LSP1-2111 and WAY100635 were
administered 45 min before the experiments. The adminis-
tration schedule of the compounds was adapted from the
other studies, but also was based on our long-lasting experi-
ence with the ligands used. The doses and routes of admin-
istration of LSP1-2111 used in the present study were the
same as those used in our previous studies concerning the
mechanisms of anxiolytic and antipsychotic action of this
compound (see Wierońska et al. 2010, 2012a, b). A dose of
WAY100635 was taken from the studies of Homberg et al.
(2008), Iijima et al. (2007), Olivier et al. (1998, 2008). The
administration schedule of (R)-(+)-8-Hydroxy-DPAT hydro-
bromidewas adapted from the studies of Bubeníková-Valesová
et al. (2007), Vinkers et al. (2009), and Yu and Lewander
(1997). LSP1-2111 was administered intraperitoneally while
WAY100635 and (R)-(+)-8-Hydroxy-DPAT hydrobro-
mide were given subcutaneously (Homberg et al. 2008;
Olivier et al. 1998; Yu and Lewander 1997). In the
interaction studies, all animals received two injections:
when one of the drugs was omitted, a vehicle was given
instead. The control animals received injections of the
appropriate vehicles.
MK-801-induced deficits in social interaction in rats Social
interaction tests were performed according to the method
described by Satow et al. (2009), using a circle made of
wood, 90 cm in diameter, divided into 10×10-cm
squares by faint yellow lines. Each social interaction
test between two rats was carried out during the light
phase of the light/dark cycle. The rats were selected from
separate housing cages to make a pair for the study. The body
weights of the paired rats were matched within 20 g of
variance. The study was conducted 3.5 h after the subcutane-
ous administration of MK-801 at 0.1 mg/kg, s.c. Each pair of
rats was diagonally placed in opposite corners of the box so
that they faced away from each other. Saline was administered
as the vehicle. LSP1-2111 (0.5, 2, and 5 mg/kg) and
WAY100635 (0.1 mg/kg) were administered 45 min before
the social interaction test (together with LSP1-2111 at a dose
of 5 mg/kg), and (R)-(+)-8-Hydroxy-DPAT hydrobromide
(0.01 mg/kg) was administered 15 min before the test,
30 min after LSP1-2111 (0.5 mg/kg). The behavior of the
animals was monitored and recorded on a video recorder
located outside the box over a 10-min period. The test box
was wiped clean between each trial. The social interaction
between the two rats was determined as the total time spent
participating in social behavior such as sniffing, genital inves-
tigation, chasing, and fighting each other. The number of
episodes was counted as a separate paradigm. The treatment
groups included eight to ten animals.
Novel object recognition The method was adapted from
Horiguchi et al. (2011a, b) and Dere et al. (2007). The
animals were trained and tested in a black wooden circular
open field (100 cm in diameter, 35-cm high) with the floor
divided into 20-cm square sections. The open field was in a
dark room illuminated only by a 25-W bulb. On the first day
(adaptation), the animals were allowed to explore the open
field for 10 min. On the next day (training, T1), the animals
were administered with the tested drugs, placed in the ap-
paratus and allowed to explore two identical objects (cylin-
der-shaped objects with walls painted white, 7 cm in
diameter, 11-cm high) for the time required to complete
15 s of exploration of either object. For the retention trial
(T2) conducted 1 h later, one of the objects presented in T1
was replaced with a novel object (a prism-shaped object
with walls painted black, 5-cm wide, 14-cm high). The rats
were returned to the open field for 5 min, and the duration of
exploration (i.e., sitting in close proximity to the objects,
sniffing, or touching them) of each object was measured
separately by a trained observer. All drugs were adminis-
tered before the training (T1) session. MK-801 (0.1 mg/kg,
s.c.) was given 30 min before the session, LSP1-2111 (0.5,
2, and 5 mg/kg, i.p.) was injected 45 min before the MK-801
injections, WAY 100635 (0.1 mg/kg, s.c.) was co-
administered with LSP1-2111 (5 mg/kg), and (R)-(+)-8-Hy-
droxy-DPAT hydrobromide (0.01 mg/kg, s.c.) was injected
15 min before the test, 30 min after LSP1-2111 (2 mg/kg).
All injections were given at a volume of 1 mL/kg of the
body weight. The treatment groups included eight animals.
Locomotor activity of habituated mice The locomotor ac-
tivity was recorded individually for each animal in OPTO-
M3 locomotor activity cages (Columbus Instrument) linked
online to a compatible PC. Each cage (13×23×15 cm) was
surrounded with an array of photocell beams. Interruptions
of these photobeams resulted in horizontal activity then
defined as ambulation scores.
The locomotor activity of habituated mice was performed
as a control experiment for the studies on hyperactivity
induced by MK-801 or amphetamine. The measurements
were performed as follows: the mice were placed into
actometers for an acclimatization period of 30 min before
they were then administered with an investigated compound
and placed again into the same cages. After the correct time
that was dependent on the action of compounds (see above),
the ambulation scores were measured for 60 min. The treat-
ment groups included eight to ten animals.
MK-801- or amphetamine-induced hyperactivity The loco-
motor activity was recorded for each animal in locomotor
activity cages (according to Rorick-Kehn et al. 2007; Monn
et al. 1999; with the small modifications used in our previ-
ous studies: Pałucha-Poniewiera et al. 2008; Wierońska et
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al. 2011, 2012a, b). The mice were placed individually into
actometers for an acclimatization period of 30 min before
they were administered with i.p. injections of the LSP1-2111
(subeffective dose, 0.3 or effective dose, 5 mg/kg), then placed
again in the same cages. WAY100635 (0.1 and 3 mg/kg) was
given 45 min before the test (it was co-administered with
LSP1-2111 at a dose of 5 mg/kg), and (R)-(+)-8-Hydroxy-
DPAT hydrobromide (0.01 and 0.1 mg/kg) was given 15 min
before the test (30 min after the administration of LSP1-2111 at
a dose of 0.3 mg/kg). The mice which were not given
WAY100635 or (R)-(+)-8-Hydroxy-DPAT hydrobromide were
administered with the saline. Then the mice were intraperito-
neally injected with MK-801 at a dose of 0.3 mg/kg or am-
phetamine at a dose of 3 mg/kg and once again returned to the
same cage. From then on, the ambulation scores were counted
for 60 min. All of the groups were compared with the MK-801
or amphetamine control group. The experiment also included a
control group that was not treated with MK-801 or amphet-
amine. The treatment groups included eight to ten animals.
Head twitch test The experiments were performed accord-
ing to our previous studies (Pałucha-Poniewiera et al. 2008;
Wierońska et al. 2011, 2012b). Briefly, in order to habituate
mice to the experimental environment, each animal was
transferred to a 12-cm (diameter) × 20-cm (height) glass
cage, lined with sawdust, 30 min before the treatment. The
head twitches of the mice were induced by DOI (2.5 mg/kg,
i.p.). Immediately after the treatment, the number of head
twitches was counted during a 20-min session. LSP1-2111
was administered in effective and subeffective doses (5 or
0.3 mg/kg, i.p., respectively), WAY100635 was adminis-
tered at a dose 0.1 mg/kg, s.c. and (R)-(+)-8-Hydroxy-DPAT
hydrobromide at a dose of 0.01 mg/kgs.c. The compounds
were given at the time schedule described above. The treat-
ment groups included eight to ten animals.
Statistical analysis The data are presented as the means ±
S.E.M. Statistical analysis of the data was performed using
the Statistica 10 package (StatSoft, Inc., OK, USA). A one-
way ANOVA followed by the Tukey’s post hoc comparison
was used in the dose-dependence studies while a two-way
ANOVA, followed by Newman–Keuls post hoc comparison
test, was used in the interaction studies. A P value of at least
p<0.05 was considered as statistically significant.
Results
The effect of LSP1-2111 on the MK-801-induced deficits in
the social interaction test Subcutaneous administration of
MK-801 at 0.1 mg/kg significantly decreased the total du-
ration of the social interaction between two naive rats and
the total number of social episodes when compared to the
vehicle-treated group. LSP1-2111 administered 45 min be-
fore the test significantly improved social withdrawal in-
duced by MK-801 (Fig. 1a, b), without affecting the
behavior of the animals when administered on its own
(Fig. 2c, d).
One-way ANOVA followed by Tukey’s post hoc com-
parison revealed that LSP1-2111 at the doses of 2 and
5 mg/kg reversed MK-801-induced deficits in the social
interaction, increasing both the number of episodes
[F(3.32)=30.32; P<0.001] and total duration of interac-
tions [F(3.32)=49; P<0.001]. Lowest dose (0.5 mg/kg)
was ineffective (Fig. 1a, b).
The effect of the combined administration of WAY100635 and
LSP1-2111 in the social interaction test in rats WAY100635
was given at a dose of 0.1 mg/kg, s.c., 45 min before the
Fig. 1 Effects of LSP1-2111 on MK-801-induced deficits in social
interaction. The number of episodes of social contacts (a) and time of
social interaction (b) were measured. Data are presented as means ±
SEM. Doses in milligrams are indicated in parentheses. #P<0.001
versus controls, **P<0.001 versus MK-801-treated group
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test, and LSP1-2111 was given at a dose of 5 mg/kg, i.p. also
45 min before the test. WAY100635, which itself was
inactive, when given with LSP1-2111, antagonized
LSP1-2111-induced antipsychotic effect in the social in-
teraction test (Fig. 2a, b). Two-way ANOVA main effects
analysis of the number of episodes revealed the signifi-
cant effect of LSP1-2111 [F(1.33)=16.83; P<0.0002], a sig-
nificant effect of WAY100635 [F(1.33)=38.5; P<0.001]
and significant LSP1-2111xWAY100635 interaction [F(1.33)=
36.66, P<0.001]. Post hoc Newman–Keuls analysis revealed
the significant effect of LSP1-2111 when compared to the
MK-801-treated animals, P<0.0001, and also significant
LSP1-2111xWAY100635 interaction, P<0.0001, when com-
pared to LSP1-2111-treated group. Two-way ANOVA analy-
sis of the time of interaction revealed significant effect of
LSP1-2111 [F(1.33)=6.42; P<0.01], significant effect of
WAY100635 [F(1.33)=8.7; P<0.005] and significant ef-
fect of LSP1-2111xWAY100635 interaction [F(1.33)=21.3;
P<0.0001]. Post hoc Newman–Keuls analysis revealed the
significant effect of LSP1-2111 when compared to the MK-
801-treated animals, P<0.0001, and also significant LSP1-
2111xWAY100635 interaction, P<0.0005, when compared to
LSP1-2111-treated rats (Fig. 2a, b).
The control experiment with the groups of LSP1-2111,
WAY100635, and LSP1-2111+WAY100635 revealed that
LSP1-2111, WAY100635, or LSP1-2111+WAY100635
interaction had not any influence on the number of episodes
and time of interaction [F(1.34)=0.78] (Fig. 2c, d).
The effect of combined administration of (R)-(+)-8-Hy-
droxy-DPAT hydrobromide and a subeffective dose of
LSP1-2111 in the social interaction test in rats (R)-(+)-8-
Hydroxy-DPAT hydrobromide was given at a dose of
0.01 mg/kg, s.c., 15 min before the test, and LSP1-2111
was given at a dose of 0.5 mg/kg, i.p. 45 min before the test.
Concomitant administration of the subeffective doses of 5-
HT1A and mGlu4 activators induced clear antipsychotic
effect in the social interaction test (Fig. 3a, b). Two-way
ANOVA main effects analysis of the number of episodes
revealed the significant effect of LSP1-2111 [F(1.36)=8.5;
P<0.005], a significant effect of (R)-(+)-8-Hydroxy-DPAT
hydrobromide [F(1.36)=4.7; P<0.03], and significant LSP1-
2111x(R)-(+)-8-Hydroxy-DPAT hydrobromide interaction
[F(1.36)=5.7; P<0.02]. Post hoc Newman–Keuls analysis
revealed the significant effect of LSP1-2111x(R)-(+)-8-Hy-
droxy-DPAT hydrobromide only, P<0.002, when compared
to all other groups. Two-way ANOVA analysis of the time
of interaction revealed a significant effect of LSP1-2111
[F(1.36)=5.5; P<0.01], significant effect of (R)-(+)-8-Hy-
droxy-DPAT hydrobromide [F(1.36)=11.05; P<0.001] and
significant effect of LSP1-2111x(R)-(+)-8-Hydroxy-DPAT
hydrobromide interaction [F(1.36)=12.2; P<0.001]. Post
Fig. 2 Effects on MK-801-
induced deficits in social
interaction. The number of
episodes of social contacts
(a, c) and time of social
interaction (b, d) were
measured. a, b Effects of
combined administration of
LSP1-2111 and WAY100635 c,
d control experiments with the
same group treatment. Data are
presented as means ± SEM.




treated group and at least
@P<0.003 versus LSP1-2111-
treated group
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hoc Newman–Keuls analysis revealed the significant effect
of LSP1-2111x(R)-(+)-8-Hydroxy-DPAT hydrobromide in-
teraction only, P<0.001, when compared to all the other
groups (Fig. 3a, b).
The control experiment with the groups of LSP1-2111,
(R)-(+)-8-Hydroxy-DPAT hydrobromide, and LSP1-2111+
(R)-(+)-8-Hydroxy-DPAT hydrobromide revealed that nei-
ther LSP1-2111, (R)-(+)-8-Hydroxy-DPAT hydrobromide,
nor LSP1-2111+(R)-(+)-8-Hydroxy-DPAT hydrobromide
interaction had any influence on the behavior of animals
[F(1.36)=0.86] (Fig. 3c, d).
The effect of LSP1-2111 on the MK-801-induced deficits in the
novel object recognition test Subcutaneous administration
of MK-801 at 0.1 mg/kg significantly decreased the
recognition index when compared with the vehicle-
treated group. LSP1-2111 given 45 min before the test
significantly improved deficits in the novel object recog-
nition induced by MK-801. One-way ANOVA followed
by Tukey’s post hoc comparison revealed that LSP1-
2111 at a dose of 5 mg/kg reversed MK-801-induced
deficit [F(3.28)=5.9; P<0.01] (Fig. 4a), without affecting
the behavior of the animals when administered alone
(Fig. 4d). Lower doses (0.5 and 2 mg/kg) were ineffec-
tive (Fig. 4a).
The effect of combined administration of WAY100635 and
LSP1-2111 in the novel object recognition test in rats
WAY100635 was given at a dose of 0.1 mg/kg, s.c., 45 min
before the test, and LSP1-2111 was given at a dose of 5 mg/kg,
i.p. also 45 min before the test. WAY100635, which
itself was inactive, antagonized LSP1-2111-induced an-
tipsychotic effect in the NOR test (Fig. 4b). Two-way
ANOVA main effects revealed statistical effect of LSP1-
2111 [F(1.28) =17.7; P<0.0002], statistical effect of
WAY100635 [F(1.28)=10.32; P<0.003], and statistical effect
of LSP1-2111xWAY100635 interaction [F(1.28) =7.7;
P<0.01]. Post hoc Newman–Keuls comparison revealed that
WAY100635 antagonized LSP1-2111-induced effect, de-
creasing recognition index in the statistically significant way,
P<0.0003, compared to LSP1-2111-treated animals (Fig. 4b).
The control experiment with the groups of LSP1-2111,
WAY100635, and LSP1-2111+WAY100635 revealed that
neither of the combination interaction had any influence on
the recognition index [F(1.28)=0.92] (Fig. 4d).
The effect of combined administration of (R)-(+)-8-Hydroxy-
DPAT hydrobromide and a subeffective dose of LSP1-2111 in
the novel object recognition test in rats (R)-(+)-8-Hydroxy-
DPAT hydrobromide was given at a dose of 0.01 mg/kg,
s.c., 15 min before the test, and LSP1-2111 was given at a
Fig. 3 Effects on MK-801-
induced deficits in social
interaction. The number of
episodes of social contacts (a,
c) and time of social interaction




hydrobromide c, d control
experiments with the same
group treatment. Data are
presented as means ± SEM.
Doses in milligrams are
indicated in parentheses.
#P<0.001 versus controls, at
least **P<0.002 versus MK-
801-treated group
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dose of 2 mg/kg, i.p. 45 min before the test. Concomitant
administration of the subeffective doses of 5-HT1A and mGlu4
activators induced clear antipsychotic effect in the NOR test
(Fig. 4c). The two-way ANOVA main effects revealed the
statistical effect of LSP1-2111 [F(1.28)=5.6; P<0.02],
statistical effect of (R)-(+)-8-Hydroxy-DPAT hydrobro-
mide [F(1.28)=11.04; P<0.01], and statistical effect of LSP1-
2111x(R)-(+)-8-Hydroxy-DPAT hydrobromide interaction
[F(1.28)=6.8; P<0.01]. Post hoc Newman–Keuls comparison
revealed the statistical effect of LSP1-2111x(R)-(+)-8-Hy-
droxy-DPAT hydrobromide interaction only, P<0.001
(Fig. 4c). The control experiment with the groups of LSP1-
2111, (R)-(+)-8-Hydroxy-DPAT hydrobromide, and LSP1-
2111+(R)-(+)-8-Hydroxy-DPAT hydrobromide revealed that
neither of the combination interactions had any influence on
the recognition index [F(1.28)=0.87] (Fig. 4d).
The effects of LSP1-2111, WAY100635, and (R)-(+)-8-Hy-
droxy-DPAT hydrobromide on locomotor activity in mice ha-
bituated to activity meters Two-way ANOVA revealed that
LSP1-2111 (5 and 0.3 mg/kg, 45 min before the test),
(R)-(+)-8-Hydroxy-DPAT hydrobromide (0.01 mg/kg,
15 min before the test), and WAY100635 (0.1 mg/kg,
45 min before the test) did not change the locomotor
activity of mice adapted to activity meters for 30 min
(Fig. 5a). No statistically significant effect from the co-
administration of LSP1-2111 (0.3 mg/kg) with (R)-(+)-8-
Hydroxy-DPAT hydrobromide (0.01 mg/kg) was observed
(Fig. 5b). However, a significant reduction of locomotor
activity after the combined co-administration of LSP1-
2111 (5 mg/kg) and WAY100635 (0.1 mg/kg) 45 min
before the measurements [F(1.31) = 9.94; P<0.003]
(Fig. 5a, b) was noticed, as well as the increase of the
ambulation scores after the administration of 8-OH-DPAT
at the higher dose of 0.1 mg/kg (Fig. 5c).
The effect of MK-801 and amphetamine on locomotor ac-
tivity in mice MK-801, at a dose of 0.3 mg/kg, produced a
robust increase in the ambulation scores (up to 574–889 %
of the control, P<0.0009) within 60 min of the experimental
session than the saline-treated animals (Figs. 6a, b and 7a,
b). Similar results were observed after the administration of
amphetamine at a dose of 3 mg/kg, i.p. The increase in
ambulation scores was observed as going up to 536–
688 %, P<0.0005, compared to the vehicle-treated animals
(Fig. 8a, b).
Fig. 4 Effects on MK-801-
induced deficits in NOR. The
dose-dependent effect of LSP1-
2111 (a), the combined
administration of LSP1-2111
(5 mg/kg) with WAY100635
(0.1 mg/kg) (b), and the
coadministration of LSP1-2111
with (R)-(+)-8-Hydroxy-DPAT
hydrobromide (c) are presented.
d Control experiments with the
same group treatments. Data are
presented as means ± SEM.




treated group and @P<0.003
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The effect of the combined administration of WAY100635 and
LSP1-2111 on MK-801-induced hyperactivity in mice -
WAY100635, when given at the ineffective dose of 0.1 mg/kg
with LSP1-2111 (5 mg/kg), antagonized LSP1-2111-induced
an antipsychotic effect in the hyperactivity test (Fig. 6a). The
two-way ANOVA main effects analysis revealed the signifi-
cant effect of LSP1-2111 [F(1.29)=8.65; P<0.006], a signifi-
cant effect of WAY100635 [F(1.29)=4.58; P<0.04], and
significant LSP1-2111xWAY100635 interaction [F(1.29)=
6.66; P<0.015]. Post hoc Newman–Keuls analysis revealed
the significant effect of LSP1-2111 when compared to the
MK-801-treated animals, P<0.002, and also significant
LSP1-2111xWAY100635 interaction, P<0.002, when com-
pared to LSP1-2111 (Fig. 6a). Such an antagonistic effect was
not observed when WAY100635 was administered at a higher
dose of 3 mg/kg, which produced a statistically significant
antipsychotic effect (F(1.40)=18.31; P<0.01) (Fig. 6b).
The effect of the combined administration of (R)-(+)-8-
Hydroxy-DPAT hydrobromide and LSP1-2111 on MK-801-
induced hyperactivity in mice Concomitant administration
of the subeffective doses of 5-HT1A and mGlu4 activators
Fig. 5 Locomotor activity of mice habituated to locomotor activity
cages. The bars represent means ± SEM. Ambulation scores were mea-
sured for 60 min after an appropriate time of drug administration. Doses
in milligrams are indicated in parentheses. *P<0.003 versus control
group
Fig. 6 The effect of the combined administration of WAY100635 and
LSP1-2111 on MK-801-induced hyperactivity in mice. Concomitant
administration of LSP1-2111 with WAY100635, 5HT1A receptor an-
tagonist at a low dose at 0.1 mg/kg (and at the higher dose 3 mg/kg (b).
LSP1-2111 and WAY100635 were given 45 min before MK-801.
Doses in milligrams are indicated in parentheses. Locomotor activity
was measured immediately after psychostimulant agent administration.
Bars represent means ± SEM. #P<0.001 versus the control group,
**P<0.01 versus MK-801 and at least @P<0.02 versus the MK-
801+LSP1-2111-treated group
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induced clear antipsychotic effect in the hyperactivity test
(Fig. 7a). The two-way ANOVAmain effects analysis revealed
the significant effect of the 8-OH-DPATxLSP1-2111 interac-
tion [F(1.30)=4.43, P<0.04]. Post-hoc Newman-Keuls analysis
revealed the significant effect of 8-OH-DPATxLSP1-2111
when compared to the MK-801-treated animals, P<0.01
(Fig. 6b). The attenuation of the MK-801-induced hyperloco-
motion reached 40 %. Such an addictive effect was not ob-
served when (R)-(+)-8-Hydroxy-DPAT hydrobromide was
given at a higher dose of 0.1 mg/kg (Fig. 7b).
The effect of the combined administration of WAY100635
and LSP1-2111 on amphetamine-induced hyperactivity in
mice WAY100635, when given with LSP1-2111,
antagonized LSP1-2111-induced antipsychotic effect in the
amphetamine-induced hyperactivity test (Fig. 8a). The two-
way ANOVA main effects analysis revealed the significant
effect of LSP1-2111 [F(1.31)=10.23; P<0.003], the signifi-
cant effect of WAY100635 [F(1.31)=16.52; P<0.0003] and
significant LSP1-2111xWAY100635 interaction [F(1.31)=
14.43, P<0.0006]. Post hoc Newman–Keuls analysis
revealed the significant effect of LSP1-2111 when compared
to the AMPH treated animals, P<0.0001, and significant
LSP1-2111xWAY100635 interaction, P<0.0001, when
compared to LSP1-2111 (Fig. 8a).
Fig. 7 The effect of the combined administration of (R)-(+)-8-Hydroxy-
DPAT hydrobromide and LSP1-2111 on MK-801-induced hyperactivity
in mice. Concomitant administration of LSP1-2111 with (R)-(+)-8-Hy-
droxy-DPAT, agonist at a low dose of 0.01 mg/kg (a) and at the higher
dose of 0.1 mg/kg (b). LSP1-2111 was given 45 min, and (R)-(+)-8-
Hydroxy-DPAT hydrobromide was given 15 min before MK-801 admin-
istration. Doses in milligrams are indicated in parentheses. Locomotor
activity was measured immediately after psychostimulant agent adminis-
tration. The bars represent means ± SEM. #P<0.001 versus the control
group, *P<0.01 versus MK-801-treated group
Fig. 8 The effect of the combined administration of WAY100635 and
(R)-(+)-8-Hydroxy-DPAT hydrobromide on LSP1-2111 action in am-
phetamine-induced hyperactivity in mice. Locomotor activity of mice
habituated to activity cages. Concomitant administration of LSP1-2111
with WAY100635, 5HT1A receptor antagonist (at a dose of 0.1 mg/kg)
(a) and 8-OH-DPAT, agonist (at a dose of 0.01 mg/kg) (b). LSP1-2111
and WAY100635 were given 45 min, and (R)-(+)-8-Hydroxy-DPAT
hydrobromide was given 15 min before amphetamine administration.
Doses in milligrams are indicated in parentheses. Locomotor activity
was measured immediately after psychostimulant agent administration.
The bars represent means ± SEM. #P<0.001 versus the control group;
**P<0.01 versus amphetamine group; and @P<0.009 versus the
AMPH+LSP1-2111-treated group
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The effect of the combined administration of (R)-(+)-8-Hy-
droxy-DPAT hydrobromide and a subeffective dose of LSP1-
2111 on amphetamine-induced hyperactivity in mice Con-
comitant administration of the subeffective doses of 5-HT1A
agonist and LSP1-2111 induced clear antipsychotic effect in
the amphetamine-induced hyperactivity test (Fig. 8b). The
two-way ANOVA main effects analysis revealed the signif-
icant effect of LSP1-2111x(R)-(+)-8-Hydroxy-DPAT hydro-
bromide interaction [F(1.29)=4.78, P<0.03]. Post hoc
Newman–Keuls analysis revealed the significant effect of
LSP1-2111x(R)-(+)-8-Hydroxy-DPAT hydrobromide when
compared to AMPH treated animals, P<0.009 (Fig. 8b).
The attenuation of the AMPH-induced hyperlocomotion
reached 50 %.
The effect of the combined administration of WAY100635 and
LSP1-2111 on DOI-induced head twitches in mice LSP1-
2111, administered i.p. at a dose of 5 mg/kg, produced a
significant decrease in the number of DOI-induced head
twitches in mice [F(1.28)=4.38, P<0.04]. WAY100635,
when given with LSP1-2111, antagonized LSP1-2111-
induced antipsychotic effect in the DOI-induced head
twitches test. The effect of LSP1-2111xWAY100635 in-
teraction was significant as well [F(1.28)=7.11, P<0.012].
Post hoc Newman–Keuls analysis revealed a significant
LSP1-2111 effect, P<0.01 when compared to the con-
trols, and significant LSP1-2111xWAY100635 interaction
when compared to LSP1-2111-treated group, P<0.009
(Fig. 9a).
The effect of the combined administration of (R)-(+)-8-Hy-
droxy-DPAT hydrobromide and a subeffective dose of LSP1-
2111 on DOI-induced head twitches in mice Concomitant
administration of the subeffective doses of 5-HT1A and
LSP1-2111 induced clear antipsychotic effect in the DOI-
induced head twitch test. The two-way ANOVA main
effects analysis revealed the significant effect of LSP1-
2111x(R)-(+)-8-Hydroxy-DPAT hydrobromide interaction
[F(1.30)=8.6, P<0.006]. Post hoc Newman–Keuls analysis
revealed the significant effect of LSP1-2111x(R)-(+)-8-Hy-
droxy-DPAT hydrobromide when compared to the DOI-
treated animals, P<0.0001 (Fig. 9b). The attenuation of
the DOI-induced head twitches reached 40 %.
Discussion
In the present manuscript, we report two major findings.
Firstly, LSP1-2111, the group III mGlu receptors’ orthos-
teric agonist, shows activity in reversing the behavioral
deficits predictive of negative and cognitive symptoms of
psychosis in the animal models. Secondly, serotonin acting
via 5-HT1A receptors (of possibly presynaptic placement)
is involved in the action of the compound in the models
of cognitive, negative, and positive symptoms of the
disease.
LSP1-2111 is a substance with a 2-year history that binds
group III mGlu receptors with preferential activity towards
the mGlu4 subtype (EC50=2.2±0.27 for mGlu4 vs. 52.87±
20.66 for mGlu7 and 65.97±11.81 for mGlu8 receptors)
(Beurrier et al. 2009). Concomitantly, it was shown that
LSP1-2111 exhibited no off-target interaction towards other
families of ionotropic and G-protein coupled receptors, and
transporters (Flor and Acher 2012).
The antipsychotic-like action of LSP1-2111 was demon-
strated by us recently in models predictive of positive symp-
toms of schizophrenia, such as MK-801 or amphetamine
hyperlocomotions, and DOI-induced head twitches in mice
(Wierońska et al. 2011, 2012b). In the present experiments
we show, that the drug is also active in an animal model of
Fig. 9 DOI-induced head twitches in mice. LSP1-2111 was given 45
min before the test. WAY100635 (a) was also injected 45 min while
(R)-(+)-8-Hydroxy-DPAT hydrobromide (b) 15 min before the test.
The number of head twitches was measured immediately after DOI
administration. The bars represent means±SEM. *P<0.01 versus the
DOI control group, and at least #P<0.009 versus the LSP1-2111
group
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negative symptoms. We used the social interaction test,
described earlier by Satow et al. (2009), with small modifi-
cations. The number of social episodes between rats and the
total duration of those contacts were measured as the param-
eters indicating social behavior.
MK-801, an NMDA channel blocker, disrupted the social
interactions decreasing both the number of social episodes
between rats and the duration of interaction. These deficits
were reversed in a dose-dependent manner after LSP1-2111
administration, with a clear effect observed at a doses of 2 and
5 mg/kg. The drug did not influence the basal social interac-
tion, indicating that positive effects of the compound in the test
were not due to apparent behavioral activation or inhibition.
Apart from negative symptoms of schizophrenia, the
efficacy of the orthosteric agonists of group III of the mGlu
receptors towards cognitive disturbances had not been in-
vestigated previously and, as such, we decided to focus also
on that aspect of LSP1-2111-induced action. We used the
novel object recognition test, which is based on the rodents’
tendency to explore unknown objects in their environment,
thus spending more time on sniffing the novel versus the
familiar object (Dere et al. 2007). In our experiments, the
animals were familiarized with two objects and, after a
1-h delay, they were presented with one familiar and one
additional object, which was regarded as a novel object,
delays longer than 1 h led to weak or no NOR effects.
Because the animals must discriminate between the exposed
previously familiar object and novel object that is presented
for the first time, the NOR is considered to be a recognition
memory task (Barak and Weiner 2011).
In the studies described herein, MK-801 was used to
induce the disruption in the NOR performance. LSP1-2111
reversed the MK-801-induced deficit at the dose of 5 mg/kg.
Simultaneously, the compound did not influence the behav-
ior of the animals when given alone.
As our recent data show that selective positive mGlu4
receptor allosteric modulators, Lu AF21934 and Lu
AF32615, were effective in tests used to investigate posi-
tive, negative, and cognitive symptoms (Sławińska et al.
2013, submitted), we are inclined to assume that the effec-
tiveness of LSP1-2111 may be predominantly related to the
stimulation of mGlu4 receptors. We are aware that we can-
not exclude the involvement of mGlu8 stimulation in the
LSP1-2111-induced action; however, because of a 30-fold
higher affinity of the compound towards mGlu4 vs. mGlu8
receptor, the compound would mainly stimulate mGlu4
receptors especially at low doses used (Beurrier et al.
2009). However, further studies with mGlu8 selective
ligands are highly desired. Although LSP1-2111 displays a
similar potency on mGlu4 and mGlu6 receptors, the exclu-
sive expression of the mGlu6 receptor in the retina precludes
any action of this compound outside this structure. On the
basis of our previous studies, we can state that the
stimulation of the mGlu7 receptor is not involved in
the antipsychotic-like effect of LSP1-2111 as AMN082
(a mGlu7 PAM) did not induce such an effect (Wierońska et
al. 2012b).
The propsychotic effects of NMDA receptor antagonist
can be explained by the impairment of the NMDA receptor
function at the GABAergic interneurons. The subsequent
loss of inhibitory control over glutamatergic pyramidal neu-
rons leads to glutamatergic hyperactivity, which is responsi-
ble for behavioral deficits described as positive, negative,
and cognitive disturbances (Javitt 1987; Conn et al. 2009).
The effectiveness of group II mGlu receptor agonists (Amitai
and Markou 2010; Patil et al. 2007; Uslaner et al. 2009) and
mGlu5 receptor stimulators (Kanuma et al. 2010) may result
from counteracting the glutamatergic hyperactivity (Linden
and Schoepp 2006). The prevention of glutamatergic hyper-
activity by inhibiting glutamate release via stimulation of
mGlu4 receptors might explain the antipsychotic-like effects
of LSP1-2111.
As the major limitation of antipsychotic therapy presently
used is its poor efficacy towards negative and cognitive
symptoms, the results presented here suggest that stimula-
tion of the mGlu4 receptor may represent a promising ther-
apeutic strategy for the future.
In the second part of our investigations, we explored the
possible involvement of the serotonergic system in the
mechanisms of the antipsychotic-like action of LSP1-2111,
focusing on the role of 5-HT1A receptors. The involvement
of that subtype in psychosis was postulated several times for
a number of reasons. Firstly, the increased 5-HT1A receptor
level was observed in the postmortem study of the cerebral
cortex and hippocampus of schizophrenic patients (Burnet
et al. 1996; Simpson et al. 1996). Secondly, selected atypical
antipsychotics, such as, clozapine or perospiron, were
shown to be partial agonists of 5-HT1A receptors (Ichikawa
et al. 2002; Hagiwara et al. 2008). Thirdly, an agonist of 5-
HT1A receptor, 8-OH-DPAT, at the low doses, induced
antipsychotic-like effects in the prepulse inhibition, the
MK-801-induced hyperlocomotion (Bubeníková-Valesová et
al. 2007), and in the social interaction deficits (Boulay et al.
2004). However, 8-OH-DPATused in those studies stimulated
not only 5-HT1A receptors but also had a moderate affinity
towards 5-HT7 receptors (Wood et al. 2000). In the present
experiments, we used a more active enantiomer of the com-
pound, e.g., (R)-(+)-8-OH-DPAT, a full agonist of 5-HT1A
receptors. The second compound used, WAY100635,
was a selective, silent antagonist of 5-HT1A receptors
(IC50=2.2 nM). Both ligands were shown to be active at the
somatodendritic 5-HT1A receptors located on the dorsal
raphe serotonergic neurons and at the postsynaptic recep-
tors (Fletcher et al. 1996; Yu and Lewander 1997). In
addition, the action of the compounds is believed to be dose-
dependent, e.g., lower doses are supposed to preferentially
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bind somatodendritic autoreceptors as shown in several papers
before (Ago et al. 2003; Sakaue et al. 2000; Artigas et al.
1996; Barnes and Sharp 1999). Therefore, in the present
studies we used low doses of the compounds (WAY100635
at 0.1 mg/kg and (R)-(+)-8-OH-DPAT at 0.01 mg/kg) that did
not have any activity on its own. Our previous experiments
revealed thatWAY100635 at the dose of 0.1 mg/kg effectively
antagonized the antidepressant and anxiolytic effects of mGlu
ligands (Stachowicz et al. 2009; Pałucha-Poniewiera et al.
2010; Wierońska et al. 2010), and the dose of (R)-(+)-8-OH-
DPATwas based on the study of Yu and Lewander (1997), and
also our preliminary experiments that showed that the
dose of 0.01 mg/kg was the minimal ineffective dose
(the antipsychotic-like effects were observed at the dose
of 0.025, data not shown).
The pretreatment of animals withWAY100635 (0.1mg/kg)
fully antagonized the action of LSP1-2111 that was adminis-
tered at the highest effective dose of 5 mg/kg. WAY100635
inhibited the action of LSP1-2111 in: hyperactivity, head
twitches, social interactions, and NOR tests. Concomi-
tantly, in all of these procedures the clear antipsychotic-
like action was evident after co-administration of sub-
effective doses of LSP1-2111 and (R)-(+)-8-OH-DPAT.
The control experiments eliminated the potential false
effect as neither of the combinations of LSP1-2111 with
the 5HT1A receptor agonist/antagonist influenced basal
behavioral activity in any way that could influence the
results. Only the combination of LSP1-2111 with
WAY100635 decreased the basal locomotor activity of
mice habituated to locomotor activity cages; although,
as the WAY100635 reversed the effect of LSP1-2111 on
MK-801 or amphetamine hyperactivity and increased
rather than decreased the ambulation scores, this aspect
of interaction may be disregarded in our considerations.
The important thing is, that those interactions between
5-HT1A-mGlu4 receptors were not observed when higher
doses of 5-HT1A receptor ligands were administered, as
shown in the MK-801-induced hyperactivity test as an
example.
On the basis of the results described above, the seroto-
nergic profile of the antipsychotic-like effectiveness of
LSP1-2111 is beginning to emerge, and the 5-HT1A receptor
seems to play a substantial role in its action. This phenom-
enon can be explained at least in two ways.
1. It has been shown that the non-competitive NMDA
receptor antagonists may enhance the expression of
serotonergic stimulation, which may contribute to the
pathogenesis of schizophrenia (Dall'Olio et al. 1999).
Accordingly, the stimulation of somatodendritic 5-HT1A
receptors by DPAT may abolish abnormal serotonergic
activity and thus induce an antipsychotic-like effect.
As the support for this statement the decrease of
concentration of 5-hydroxyindoleacetic acid (5-HIAA),
that indicates a decrease in turnover of 5-HT (Larsson et
al. 1990), and the reduced extracellular 5-HT level in the
striatum (Allen et al. 1997), were observed after 8-OH-
DPAT administration.
2. The pattern of expression of 5-HT1A receptors may also
constitute a key culprit of this phenomenon. Nearly
50 % of pyramidal neurons in the cortex are positive
for the 5-HT1A receptors which are expressed on the
axonal hillocks (Wedzony et al. 2008). These heterore-
ceptors would inhibit the glutamate release after activa-
tion, and this aspect of serotonergic agonist action may
be important in light of the glutamatergic theory of
psychosis. Thus, synergism between LSP1-2111 and
(R)-(+)-8-OH-DPAT actions may develop due to the
activation of mGlu4/8 autoreceptors and 5-HT1A hetero-
receptors expressed on glutamatergic terminals. Stimu-
lation of both subtypes may play in concert resulting in
the inhibition of glutamate release. Although the de-
tailed colocalization studies on the 5-HT1A-mGlu4/8
receptors are lacking, we can speculate that those recep-
tors may colocalize. It is known that relationships be-
tween mGlu2/3 and 5-HT2A receptors exist (González-
Maeso et al. 2008) and are involved in the antipsychotic
activity of group II mGlu receptor ligands (Amitai and
Markou 2010; Marek et al. 2000; Uslaner et al. 2009).
Therefore, it can be hypothesized that the dimerization
between 5-HT1A and mGlu4 receptors also occur and may
be involved in the interactions between the LSP1-2111
and 5-HT1A receptor ligands observed here. Together
with the effects of the stimulation of somatodendritic 5-
HT1A receptors described above in raphe nuclei (point 1),
5-HT1A and mGlu4/8 receptors may represent a promising
tandem (or triplet) in schizophrenia research.
The fact that the (R)-(+)-8-OH-DPAT at the ten times
higher dose of 0.1 mg/kg did not act synergistically with
LSP1-2111 may confirm our hypothesis that the activation
of presynaptic 5-HT1A receptors could be responsible for the
interaction with LSP1-2111. The higher doses of (R)-(+)-8-
OH-DPAT may induce a distinct behavioral change that
could be associated with the 5-HT syndrome, related to 5-
HT1A selective activation such as changes in locomotor
activity, flat body posture, and forepaw treading (Blanchard
et al. 1997; Yu and Lewander 1997; Goodwin et al. 1986,
1987; Larsson et al. 1990).
Also, the fact that WAY100635 at a dose of 3 mg/kg did
not block the action of LSP1-2111 further enhances the
probability that presynaptic 5-HT1A receptors are mainly
involved in the interactions described in this paper. This
dose of WAY100635 produced an antipsychotic effect con-
firming that data of Wedzony et al. (2000), who described
such an effect of WAY100135.
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To summarize: the proper activity of pyramidal neurons
and the functional integrity between both the glutamatergic
and serotonergic system may be crucial for efficient
antipsychotic treatment. The data suggest that cooperation
between group III Glu receptor and 5-HT1A receptor
agonists may be efficient in attenuating not only positive
symptoms but may be especially important in other
key features of schizophrenia poorly controlled by
dopamine-based antipsychotics, namely social functioning
and cognitive disturbances.
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